MX2018003376A - Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. - Google Patents
Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.Info
- Publication number
- MX2018003376A MX2018003376A MX2018003376A MX2018003376A MX2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A MX 2018003376 A MX2018003376 A MX 2018003376A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- therapeutic agent
- pathway
- biomarkers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562220062P | 2015-09-17 | 2015-09-17 | |
| PCT/US2016/052060 WO2017049035A1 (en) | 2015-09-17 | 2016-09-16 | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018003376A true MX2018003376A (es) | 2018-08-15 |
Family
ID=58289919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003376A MX2018003376A (es) | 2015-09-17 | 2016-09-16 | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11016099B2 (https=) |
| EP (1) | EP3349854A4 (https=) |
| JP (3) | JP6909208B2 (https=) |
| KR (1) | KR20180063127A (https=) |
| CN (2) | CN116672446A (https=) |
| AU (1) | AU2016323579A1 (https=) |
| BR (1) | BR112018005175A2 (https=) |
| CA (1) | CA2998349A1 (https=) |
| HK (1) | HK1258292A1 (https=) |
| IL (1) | IL257969A (https=) |
| MX (1) | MX2018003376A (https=) |
| RU (1) | RU2018113694A (https=) |
| WO (1) | WO2017049035A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| WO2016054038A1 (en) | 2014-09-29 | 2016-04-07 | Immusant, Inc. | Use of hla genetic status to assess or select treatment of celiac disease |
| JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| WO2019113037A1 (en) * | 2017-12-04 | 2019-06-13 | Immusant, Inc. | Measurement of ccl20 after gluten exposure |
| CA3085000A1 (en) * | 2017-12-07 | 2019-06-13 | Amgen Inc. | Method of treating idiopathic thrombocytopenia purpura (itp) with romiplostim |
| CA3092551A1 (en) * | 2018-03-05 | 2019-09-12 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
| EP3793521A4 (en) | 2018-05-18 | 2022-02-23 | Janssen Biotech, Inc. | SAFE AND EFFECTIVE METHOD OF TREATING LUPUS WITH AN ANTI-IL12/IL23 ANTIBODY |
| WO2020016838A2 (en) * | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained response predictors after treatment with anti-il23 specific antibody |
| BR112021005467A2 (pt) * | 2018-09-24 | 2021-06-22 | Janssen Biotech, Inc. | método seguro e eficaz para tratar colite ulcerativa com anticorpo anti-il12/il23 |
| WO2020104705A2 (en) * | 2018-11-23 | 2020-05-28 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
| CN109337974B (zh) * | 2018-12-14 | 2022-01-25 | 北京蛋白质组研究中心 | 一种检测银屑病的诊断标志物的试剂及其应用 |
| US20200197517A1 (en) * | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody |
| MX2021011328A (es) * | 2019-03-18 | 2021-12-10 | Janssen Biotech Inc | Método para tratar la psoriasis en sujetos pediátricos con anticuerpo anti-il12/il23. |
| CN113710316A (zh) * | 2019-03-26 | 2021-11-26 | 阿斯特捷利康合作创业有限责任公司 | 适合于il23拮抗剂疗法的患者群体 |
| EP3956358A4 (en) * | 2019-04-17 | 2023-01-25 | Millennium Pharmaceuticals, Inc. | COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR |
| WO2020234834A1 (en) | 2019-05-23 | 2020-11-26 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
| US20210079086A1 (en) * | 2019-08-21 | 2021-03-18 | Astrazeneca Collaboration Ventures, Llc | Use of Brazikumab to Treat Crohn's Disease |
| CN114555120A (zh) * | 2019-10-18 | 2022-05-27 | 詹森生物科技公司 | 用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法 |
| WO2021106453A1 (ja) * | 2019-11-29 | 2021-06-03 | 東洋紡株式会社 | 組換えｃ反応性タンパク質 |
| CA3164996A1 (en) * | 2019-12-20 | 2021-06-14 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
| CA3170677A1 (en) * | 2020-02-14 | 2021-08-19 | Janssen Biotech, Inc. | Safe and effective method of treating ulcerative colitis with anti-il-12/il23 antibody |
| CN111424086A (zh) * | 2020-03-19 | 2020-07-17 | 上海交通大学 | 用于胃癌诊断及预后评估的生物标记物及应用和检测试剂盒 |
| WO2021207725A1 (en) * | 2020-04-10 | 2021-10-14 | The Johns Hopkins University | Lipocalin-2 assay for intestinal adaptation |
| KR20230023663A (ko) | 2020-05-21 | 2023-02-17 | 얀센 바이오테크 인코포레이티드 | Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법 |
| US20230391863A1 (en) * | 2020-10-23 | 2023-12-07 | Hq Han | Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof |
| IL303198A (en) | 2020-11-30 | 2023-07-01 | Mindera Corp | Microneedle devices, methods and skin condition tests |
| US20220373539A1 (en) * | 2021-05-24 | 2022-11-24 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| WO2025170982A2 (en) | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 antibody compositions and methods of use |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| ES2225956T3 (es) | 1996-11-01 | 2005-03-16 | Magne K. Fagerhol | Procedimiento para la extraccion de proteinas. |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
| US7226591B2 (en) | 2000-05-22 | 2007-06-05 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
| ES2316454T3 (es) | 2000-08-24 | 2009-04-16 | Genentech, Inc. | Metodo de inhibicion de pap1 inducido por il-22. |
| AU2005220910A1 (en) | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| CA2565701A1 (en) | 2004-05-06 | 2005-11-17 | Jonathan M. Barasch | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| AU2006265002B2 (en) | 2005-06-30 | 2012-09-20 | Centocor, Inc. | Anti-IL-23 antibodies, compositions, methods and uses |
| DE602006015830D1 (de) | 2005-08-25 | 2010-09-09 | Lilly Co Eli | Anti-il-23-antikörper |
| EP3190125A1 (en) | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
| PL1933869T3 (pl) * | 2005-09-01 | 2010-06-30 | Merck Sharp & Dohme | Zastosowanie antagonistów IL-23 i IL-17 do leczenia autoimmunologicznej zapalnej choroby oczu |
| SI1971366T1 (sl) | 2005-12-29 | 2014-10-30 | Janssen Biotech, Inc. | Humana protitelesa anti-il-23, sestavki, postopki in uporabe |
| US20070203216A1 (en) | 2006-02-14 | 2007-08-30 | Bjarke Ebert | Method of treating inflammatory diseases |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| CA2652924A1 (en) | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating il-22 and il-17 |
| GB0613470D0 (en) | 2006-07-06 | 2006-08-16 | Ares Trading Sa | Protein |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| EP2426145B1 (en) | 2007-02-23 | 2017-01-18 | Merck Sharp & Dohme Corp. | Engineered anti-il-23p19 antibodies |
| AR065420A1 (es) | 2007-02-23 | 2009-06-03 | Schering Corp | Anticuerpos anti-il-23 p19 de ingenieria |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| US20090123946A1 (en) | 2007-10-19 | 2009-05-14 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CA2702611A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| US20090269777A1 (en) | 2007-10-19 | 2009-10-29 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CN101910845A (zh) | 2007-11-15 | 2010-12-08 | 比奥波托诊断股份公司 | 个体分子形式的生物标志的诊断用途 |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| US7879553B2 (en) | 2008-03-14 | 2011-02-01 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| US20100227775A1 (en) | 2008-04-16 | 2010-09-09 | Abbott Laboratories | Immunoassays and kits for the detection of ngal |
| CA2734919C (en) | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| GB2464183A (en) | 2008-09-19 | 2010-04-14 | Singulex Inc | Sandwich assay |
| WO2010042903A1 (en) | 2008-10-09 | 2010-04-15 | Alfagene Bioscience, Inc | Use and identification of biomarkers for gastrointestinal diseases |
| US20100105150A1 (en) | 2008-10-24 | 2010-04-29 | Abbott Laboratories | Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| CA2757237A1 (en) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| EP2435480A1 (en) | 2009-05-27 | 2012-04-04 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| WO2010151699A1 (en) | 2009-06-25 | 2010-12-29 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| EP2451969A2 (en) | 2009-07-07 | 2012-05-16 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| BR112012012513A2 (pt) | 2009-11-25 | 2017-01-10 | Prometheus Lab Inc | método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo |
| HRP20171939T1 (hr) | 2010-01-15 | 2018-03-23 | Kirin-Amgen, Inc. | Formulacija protutijela i režimi terapije |
| EP2596022A4 (en) | 2010-07-20 | 2014-11-05 | Cephalon Australia Pty Ltd | SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23 |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| PE20141162A1 (es) | 2010-11-04 | 2014-09-18 | Boehringer Ingelheim Int | Anticuerpos anti-il-23 |
| JP6116485B2 (ja) | 2011-01-06 | 2017-04-19 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 心臓性突然死に関連する方法において使用するためのｓｃｎ５ａスプライスバリアント |
| GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
| US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
| WO2012115885A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| EP3825693A1 (en) | 2011-04-29 | 2021-05-26 | Cancer Prevention And Cure, Ltd. | Methods of identification and diagnosis of lung diseases using classification systems and kits thereof |
| EP2710383B1 (en) | 2011-05-16 | 2017-01-11 | The University of Newcastle | Performance of a biomarker panel for irritable bowel syndrome |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| CN103874770A (zh) | 2011-08-08 | 2014-06-18 | 卡里斯生命科学卢森堡控股有限责任公司 | 生物标志物组合物和方法 |
| CN106063787A (zh) * | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| ES2716995T3 (es) | 2012-04-03 | 2019-06-18 | Univ Michigan Regents | Biomarcadores asociados con el síndrome del intestino irritable y la enfermedad de Crohn |
| EP2903691B1 (en) * | 2012-10-05 | 2019-05-22 | F.Hoffmann-La Roche Ag | Methods for diagnosing and treating inflammatory bowel disease |
| WO2015175856A1 (en) | 2014-05-15 | 2015-11-19 | Meso Scale Technologies, Llc. | Improved assay methods |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| EP3172339A1 (en) | 2014-07-24 | 2017-05-31 | Boehringer Ingelheim International GmbH | Biomarkers useful in the treatment of il-23a related diseases |
| JP6909208B2 (ja) | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| GB201521357D0 (en) | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
| AU2016379157A1 (en) | 2015-12-22 | 2018-06-21 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
| US20200064357A1 (en) | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| WO2018119626A1 (zh) | 2016-12-27 | 2018-07-05 | 菲鹏生物股份有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 |
-
2016
- 2016-09-16 JP JP2018514414A patent/JP6909208B2/ja not_active Expired - Fee Related
- 2016-09-16 MX MX2018003376A patent/MX2018003376A/es unknown
- 2016-09-16 KR KR1020187010308A patent/KR20180063127A/ko not_active Withdrawn
- 2016-09-16 HK HK19100656.4A patent/HK1258292A1/zh unknown
- 2016-09-16 US US15/759,330 patent/US11016099B2/en active Active
- 2016-09-16 EP EP16847353.6A patent/EP3349854A4/en not_active Withdrawn
- 2016-09-16 CA CA2998349A patent/CA2998349A1/en not_active Abandoned
- 2016-09-16 CN CN202310427386.3A patent/CN116672446A/zh active Pending
- 2016-09-16 AU AU2016323579A patent/AU2016323579A1/en not_active Abandoned
- 2016-09-16 BR BR112018005175A patent/BR112018005175A2/pt not_active Application Discontinuation
- 2016-09-16 RU RU2018113694A patent/RU2018113694A/ru not_active Application Discontinuation
- 2016-09-16 WO PCT/US2016/052060 patent/WO2017049035A1/en not_active Ceased
- 2016-09-16 CN CN201680066986.XA patent/CN108290058B/zh not_active Expired - Fee Related
-
2018
- 2018-03-08 IL IL257969A patent/IL257969A/en unknown
-
2021
- 2021-07-02 JP JP2021110695A patent/JP7153775B2/ja active Active
-
2022
- 2022-10-03 JP JP2022159196A patent/JP2023002583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7153775B2 (ja) | 2022-10-14 |
| EP3349854A1 (en) | 2018-07-25 |
| JP2018535394A (ja) | 2018-11-29 |
| CA2998349A1 (en) | 2017-03-23 |
| JP6909208B2 (ja) | 2021-07-28 |
| CN108290058A (zh) | 2018-07-17 |
| KR20180063127A (ko) | 2018-06-11 |
| AU2016323579A1 (en) | 2018-04-05 |
| CN116672446A (zh) | 2023-09-01 |
| BR112018005175A2 (pt) | 2018-10-16 |
| CN108290058B (zh) | 2023-05-16 |
| EP3349854A4 (en) | 2019-04-03 |
| WO2017049035A1 (en) | 2017-03-23 |
| US11016099B2 (en) | 2021-05-25 |
| JP2023002583A (ja) | 2023-01-10 |
| IL257969A (en) | 2018-05-31 |
| RU2018113694A3 (https=) | 2020-01-31 |
| US20180252728A1 (en) | 2018-09-06 |
| RU2018113694A (ru) | 2019-10-17 |
| HK1258292A1 (zh) | 2019-11-08 |
| JP2021170017A (ja) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| Combe et al. | Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| NZ584787A (en) | Inhibition of angiogenesis with a Bv8 antagonist | |
| BR112014011127A2 (pt) | métodos para tratar, diagnosticar e monitorar doença de alzheimer | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| Chua et al. | Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer | |
| BR112019005274A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratar uma doença ou condição inflamatória ou autoimune, para tratar um câncer, para reduzir ou aliviar dor e para detectar expressão de gm-csf em uma amostra. | |
| Ragab et al. | Serum serotonin in rheumatoid arthritis patients: relation to rheumatoid factor positivity, clinical manifestations and fibromyalgia | |
| WO2017059276A8 (en) | Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation | |
| JP2015503106A5 (https=) | ||
| SG11201901435UA (en) | Monoclonal antibody against melk and utilization thereof | |
| UA106256U (uk) | Спосіб прогнозування зрощення перелому | |
| Navarro et al. | 299 Differential abundance of mirnas circulating in peripheral blood of patients with class iv lupus nephritis | |
| UA106255U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106228U (uk) | Спосіб прогнозування зрощення перелому | |
| Miller et al. | C80-A EVERYTHING YOU NEED TO KNOW ABOUT BRONCHOPULMONARY DYSPLASIA, CYSTIC FIBROSIS AND DIFFUSE PARENCHYMAL LUNG DISEASES: Vitamin D Binding Protein And Alpha-1-Acid Glycoprotein Levels In Serum Are Associated With Lymphangioleiomyomatosis | |
| UA106723U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106229U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106280U (uk) | Спосіб прогнозування зрощення перелому | |
| Korol et al. | PREDICTICAL VALUE OF DETERMINING THE OXIDATIVSTRESS INDEX IN BLOOD SERUM OF PATIENTS WITH PYELONEPHRITIS |